Global News

Clinical Conductor CTMS launches configurations

Wednesday, July 16, 2014 01:14 PM

The Clinical Conductor CTMS team has launched CTMS configurations for Clinical Conductor. These configurations are designed for research sites, site networks, CROs, hospitals, health systems and sponsors. With CTMS configurations, Clinical Conductor now provides unique feature sets and functionalities required by different types of research organizations to operate most effectively.

More... »

WIRB Copernicus Group

Theorem Clinical Research, Excel Life Sciences partner

Wednesday, July 16, 2014 01:13 PM

CRO Theorem Clinical Research and Excel Life Sciences (ELS) have formed a strategic relationship to bolster Theorem’s clinical development offerings in India, including local site management experience. ELS has long-standing relationships with more than 1,000 hospitals and research centers across 25 cities throughout India, covering a broad range of therapeutic disciplines.

More... »

CRF Health eCOA webinar series

Harlan Laboratories, Fluofarma collaborate

Wednesday, July 16, 2014 01:10 PM

Harlan Laboratories, a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS) business, and Fluofarma, a CRO specializing in high content analysis, have partnered to strengthen the companies’ drug discovery and translational medicine services.

More... »

Chiltern acquires Ockham, strengthening oncology, CRO services, job placement

Tuesday, July 15, 2014 03:38 PM

U.K.-based Chiltern, a 32-year-old global CRO specializing in oncology services and a range of other therapeutic areas, has acquired Ockham, a 28-year-old oncology-focused CRO, and the two companies will merge their operations.

More... »

FDA approves IDE for VENITI VICI Venous Stent System

Monday, July 14, 2014 01:33 PM

Veniti, a provider of innovative technology for the treatment of venous disease, announced has received approval from the FDA for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System. The VICI Venous Stent System was designed from inception to be compatible with the unique anatomy and pathophysiology of the venous system. Hundreds of thousands of people around the world suffer from lower-extremity venous disease, and until recently, the only treatment options available involved the use of re-purposed vascular stents originally designed for use in the arterial system.

More... »

Health Canada approves APTIOM (eslicarbazepine acetate) for epilepsy

Monday, July 14, 2014 01:13 PM

Sunovion Pharmaceuticals Canada has announced that Health Canada approved APTIOM (eslicarbazepine acetate) for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy. APTIOM is not indicated for use in patients under 18 years of age.

More... »

Covance adds two to clinical development services leadership team

Monday, July 14, 2014 01:04 PM

Covance has announced two key additions to its clinical development services scientific leadership team with the appointments of Robert Wasserman, M.D., as vice president and global therapeutic area head, oncology, and Rogelio Mosqueda-Garcia, M.D., Ph.D., as global vice president, early clinical services within medical and scientific affairs. Both are based in Princeton, N.J.

More... »

Merck's biopharmaceutical division appoints Luciano Rossetti global head of R&D

Monday, July 14, 2014 12:59 PM

Merck's biopharmaceutical division has appointed Luciano Rossetti, M.D., executive vice president and global head of R&D as of July 21.

More... »

Shire willing to discuss AbbVie’s 5th revised proposal

Monday, July 14, 2014 12:48 PM

Following discussions with AbbVie, Shirerequested and has received a further revised proposal from AbbVie on July 13 for a total offering of $53 billion.

More... »

Abbott to sell generics pharmaceuticals business to Mylan, form new entity

Monday, July 14, 2014 12:47 PM

Abbott will sell its non-U.S. developed markets branded generics pharmaceuticals business to Mylan for 105 million shares, or approximately 21%, on a fully diluted basis, of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business. The new entity will be a publicly traded company. This represents a value of approximately $5.3 billion based on Mylan's closing stock price on Friday.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs